Renal Cell Carcinoma Clinical Trials

Clinical Trial: Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Clinical Trial: Dalteparin in Combination With Sunitinib in Patients With Metastatic Kidney Cancer

Clinical Trial: Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

Clinical Trial: A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Clinical Trial: A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer

Clinical Trial: Vaccine Therapy in Treating Patients With Newly Diagnosed Stage IV Kidney Cancer

Clinical Trial: Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma

Clinical Trial: Ixabepilone in Treating Patients With Renal Cell Carcinoma (Kidney Cancer)

Clinical Trial: Dalteparin in Combination With Sunitinib in Patients With Metastatic Kidney Cancer

Clinical Trial: The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma (SELECT)

Renal Nutrition Update

For the latest nutrition news and studies, click here to visit our Renal Nutrition Update dept.

Renal & Urology News
E-Newsletters

Sign up today to start receiving one of three free e-newsletters from Renal & Urology News or get them all.
- eTOC (print edition preview)
- RUN Roundup
- Conference Highlights

Sample | Subscribe | Archive


 Subscribe to the RSS for this page  [view all our RSS feeds here]
Popular Topics
Acute Kidney Injury Anemia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease CKD Diabetes Dialysis Epidemiology Erectile Dysfunction Hemodialysis Hyperphosphatemia Hypertension Infection Kidney Cancer Kidney Stones Peritoneal Dialysis Prostate Cancer PSA Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence UTI

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions